2025-04-15 - Analysis Report
## Costco Wholesale Corp (COST) Stock Analysis Report

This report analyzes Costco Wholesale Corp (COST), a large American multinational corporation operating a chain of membership-only warehouse clubs.


**1) Performance Comparison & Alpha/Beta Analysis:**

Costco's cumulative return (293.56%) significantly outperforms the S&P 500's cumulative return (66.69%).  The difference is 226.9%, placing it at the 100th percentile of the historical range (max: 226.9, min: -14.1). This indicates COST has consistently outperformed the market over the measured period.

The Alpha/Beta analysis shows consistently positive alpha, indicating COST has generated excess returns compared to the market (Beta represents market sensitivity).  The Beta values generally range from 0.1 to 0.5, suggesting lower than average market volatility.  CAGR (Compound Annual Growth Rate) has been remarkably high in recent years, exceeding 100% in some periods, demonstrating strong growth. However, the Maximum Drawdown (MDD) also increased significantly in recent years, indicating higher risk.  The increasing market capitalization (Cap(B)) reflects the company's growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 27.0% | 55.6% | -2.0% | 0.1 | 74.3 |
| 2016-2018  | 16.0% | 61.5% | -2.0% | 0.2 | 82.2 |
| 2017-2019  | 54.0% | 61.5% | 25.0% | 0.4 | 119.7 |
| 2018-2020  | 67.0% | 80.0% | 42.0% | 0.2 | 158.8 |
| 2019-2021  | 138.0% | 80.0% | 84.0% | 0.2 | 241.1 |
| 2020-2022  | 81.0% | 80.0% | 75.0% | 0.2 | 195.2 |
| 2021-2023  | 134.0% | 71.2% | 117.0% | 0.5 | 290.8 |
| 2022-2024  | 128.0% | 81.0% | 111.0% | 0.4 | 406.1 |
| 2023-2025  | 123.0% | 81.0% | 109.0% | 0.4 | 434.5 |


**2) Recent Price Movement:**

* **Closing Price:** $979.32
* **5-day Moving Average:** $956.20
* **20-day Moving Average:** $934.96
* **60-day Moving Average:** $979.26

The price is slightly above the 60-day moving average, suggesting a relatively stable trend.  The price is significantly above the 20-day and 5-day moving averages, indicating recent upward momentum.  The recent price change ($1.65 increase) is relatively small.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4585 (High Risk)  This suggests caution.
* **RSI:** 62.93 (Neither overbought nor oversold)
* **PPO:** 0.7951 (Positive, suggesting upward momentum)
* **20-day Relative Strength Change:** +7.3 (Short-term upward trend)
* **Expected Return:** 26.7% (Long-term, relative to S&P 500)


**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-03-13 | 4.03 | $63.72 B      |
| 2024-12-19 | 4.05 | $62.15 B      |
| 2024-06-06 | 3.79 | $58.52 B      |
| 2024-03-13 | 3.93 | $58.44 B      |
| 2025-03-13 | 3.93 | $58.44 B      |

There appears to be a slight duplicate entry for 2025-03-13.  Revenue shows some fluctuation, but EPS remains relatively stable and strong. More data points are needed for a comprehensive analysis.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2025-02-28  | $63.72B   | 12.52%        |
| 2024-11-30  | $62.15B   | 12.94%        |
| 2024-08-31  | $79.70B   | 12.68%        |
| 2024-05-31  | $58.52B   | 12.55%        |
| 2024-02-29  | $58.44B   | 12.49%        |

Revenue shows seasonal variation. Profit margins remain relatively stable and high, indicating strong profitability.


**Capital and Profitability:**

| Quarter     | Equity    | ROE    |
|-------------|-----------|--------|
| 2025-02-28  | $25.58B   | 6.99%  |
| 2024-11-30  | $24.45B   | 7.35%  |
| 2024-08-31  | $23.62B   | 9.97%  |
| 2024-05-31  | $21.77B   | 7.72%  |
| 2024-02-29  | $20.76B   | 8.40%  |

Equity is steadily increasing, reflecting the companyâ€™s growth.  ROE (Return on Equity) fluctuates but generally remains strong.



**6) Overall Analysis:**

COST has demonstrated a strong track record of outperforming the S&P 500, with consistently high CAGR and positive alpha.  Recent price movements suggest upward momentum, though the high MRI indicates elevated risk.  Financials show stable and strong profitability and consistent growth.  However,  the increasing MDD in recent years warrants attention.  While long-term prospects appear positive, given the expected return, investors should monitor the market risk and potential volatility.  Further investigation into the duplicated data point in the earnings report is recommended.
